The Biomanufacturing Research Program, (BioMAN), is a collaborative research and educational program in biotherapeutic manufacturing. The objective of this program is to develop new knowledge, science, technologies and strategies that advance the manufacture and global delivery of high quality biopharmaceuticals. BioMAN activities bring together thought leaders from industry, the government/FDA and academia and involve faculty from across the Schools of Science, Engineering and Management at MIT
Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)
The mission of the Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) is to develop a comprehensive understanding of adventitious agents encountered in biomanufacturing, the sources of such agents, and a systematic, risk-based analysis of the most effective strategies and technologies to prevent contamination.
NEW Drug Development ParaDIGmS (NEWDIGS)
The New Drug Development Paradigms program (NEWDIGS) focuses on transforming the current global pharmaceutical innovation ecosystem to more reliably and sustainably deliver new, better, affordable drugs to the right patients faster. System re-engineering projects are designed and executed with input from industry; regulators from US, Europe, Singapore, and Canada; payers and health technology assessment officials; providers, patients, and academic researchers from MIT, Harvard and other leading academic institutions.
In 2010, Sanofi and CBI established a strategic alliance to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between academia and industry. The alliance provides Sanofi the opportunity to develop therapeutic, diagnostic and prognostic applications based on the discoveries made and MIT investigators the opportunity for funding and other translational resources for their research.
As part of the Alliance, Sanofi supported a number of activities at MIT, including a Biomedical Innovation Award Program managed by the MIT Center for Biomedical Innovation These financial awards provided MIT researchers with focused, flexible and rapidly available funds for translational biomedical research..
Completed Research Projects:
Economics of Stratified Medicine
Development and Validation of Tools To Enhance Decision-making Related to “Stratified Medicine”
Strategic Allocation of Global Clinical Trials
Advancing the Strategic Decision Making Process Behind the Selection of Where to Place Patient Recruitment Sites
Enhancing the Productivity of Collaborative Innovation
Comparative Analysis of Established Bioclusters in San Diego, Singapore, and Boston